Inve India ▾

Bliss GVS Pharma share price & results

Bliss GVS Pharma Limited· Healthcare

Results to
Jun 2026
Ownership as of
Sept 2026

World leader in suppositories & pessaries; exports 150+ pharma brands to 60+ countries, mainly Africa.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue222 ₹ crore+36.2% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin23.0 %+3.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit39.0 ₹ crore+85.7% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity12.37 %+3.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin9.17 %+5.1 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)20.65 %+9.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Price

₹639.25 +3.10% · +₹19.2

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +317.8% 1Y

₹200₹400₹600Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹153.01 on 24 Oct 2025 → ₹639.25. High ₹737.65 (28 Sept 2026), low ₹127.9 (7 Nov 2025).

Previous close
₹620.05
Market cap
₹6.6k Cr
52-week range
₹127.9 – ₹737.65
One year
+322.59%
Price to earnings (TTM to Jun 2026)
47.51×
Return on equity (TTM to Jun 2026)
12.37%

Overview

Symbol
NSE:BLISSGVS
Exchange
NSE
Currency
INR

What Bliss GVS Pharma Limited does

Based on the company's own presentations, annual report and earnings calls.

Bliss GVS Pharma, incorporated in 1984 and headquartered in Mumbai, manufactures and markets branded pharmaceutical formulations with a global leadership position in the suppositories and pessaries dosage forms. It runs eight manufacturing units across Maharashtra (Palghar, Ambernath, Vevoor) and Nigeria, producing tablets, suppositories/pessaries, capsules, ointments/creams/gels, sachets, dry syrups, lozenges and skincare products across therapeutic categories such as anti-malarial, anti-fungal, anti-inflammatory, anti-biotic and laxative. It earns primarily through branded exports concentrated in Sub-Saharan Africa (brands such as Lonart, Funbact, P-Alaxin, Lofnac and Gsunate) alongside in-licensed suppository manufacturing for global pharma majors including Sanofi, Alkem, Sun Pharma, Mankind, Neon and Intas.

Segments

  • Suppositories & Pessaries
  • Other Pharmaceutical Formulations
Market position
World leader in suppositories & pessaries dosage forms, with one of the largest product portfolios in this segment globally
Manufacturing facilities
8 units — 6 in Maharashtra (Palghar, Ambernath, Vevoor) and 2 in Nigeria (Nigeria units to be divested in FY26)
Countries present
60+
Brands
150+
Products manufactured
400+
Therapeutic segments
50+
Founded 1984Headquarters Mumbai, Maharashtra, India Company website

Your own record

Start an Inve Case for Bliss GVS Pharma Limited

Free account: one company. Everything above stays public.

Write why you follow Bliss GVS Pharma Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Bliss GVS Pharma Limited

Guides on how to read this kind of business and the numbers that matter.